98%
921
2 minutes
20
Merkel cell carcinoma (MCC) is an aggressive neuroendocrine skin cancer that frequently carries an integrated Merkel cell polyomavirus (MCPyV) genome and expresses viral transforming antigens (TAgs). MCC tumor cells also express signature genes detected in skin-resident, postmitotic Merkel cells, including atonal bHLH transcription factor 1 (ATOH1), which is required for Merkel cell development from epidermal progenitors. We now report the use of in vivo cellular reprogramming, using ATOH1, to drive MCC development from murine epidermis. We generated mice that conditionally expressed MCPyV TAgs and ATOH1 in epidermal cells, yielding microscopic collections of proliferating MCC-like cells arising from hair follicles. Immunostaining of these nascent tumors revealed p53 accumulation and apoptosis, and targeted deletion of transformation related protein 53 (Trp53) led to development of gross skin tumors with classic MCC histology and marker expression. Global transcriptome analysis confirmed the close similarity of mouse and human MCCs, and hierarchical clustering showed conserved upregulation of signature genes. Our data establish that expression of MCPyV TAgs in ATOH1-reprogrammed epidermal cells and their neuroendocrine progeny initiates hair follicle-derived MCC tumorigenesis in adult mice. Moreover, progression to full-blown MCC in this model requires loss of p53, mimicking the functional inhibition of p53 reported in human MCPyV-positive MCCs.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8970662 | PMC |
http://dx.doi.org/10.1172/JCI152069 | DOI Listing |
Immunotherapy
September 2025
Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
Currently, the first-line treatment of non-metastatic Merkel cell carcinoma (MCC) is complete resection. In case of unresectable or metastatic MCC, immune checkpoint inhibitor (ICI) therapy with avelumab (or in the US also pembrolizumab or retifanlimab) is indicated. We report on a patient with a primary, non-metastatic MCC on the left eyelid and amyotrophic lateral sclerosis (ALS).
View Article and Find Full Text PDFDermatol Surg
September 2025
HCA Florida Orange Park Hospital, Orange Park, Florida.
Background: Mohs micrographic surgery (MMS) allows for precise excision of skin cancers with intraoperative histologic margin assessment. Incidental findings-unexpected histopathologic features unrelated to the primary lesion-are occasionally discovered but scantily characterized in the literature.
Objective: To systematically review published cases of incidental histologic findings identified during MMS, with attention to their frequency, clinical implications, and management.
Biomed Pharmacother
September 2025
Department of Obstetrics and Gynecology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Electronic address:
Various viruses are widely recognized as key contributors to the development of numerous hematological malignancies and solid tumors. It is estimated that virus-associated cancers account for approximately 1.5 million new cases globally each year.
View Article and Find Full Text PDFDermatol Surg
September 2025
Department of Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
J Cutan Pathol
August 2025
Dermatopathology, KorPath, Tampa, Florida, USA.
Cutaneous large cell neuroendocrine carcinoma (LCNEC) is a rare and poorly understood malignancy. Here we describe the clinicopathological characteristics of six cutaneous LCNEC case. A retrospective chart and slide review of PCLCNEC cases at a large commercial dermatopathology practice from January 2017 to May 2025 was performed.
View Article and Find Full Text PDF